NCT03823703: A trial that was reported late by Corcept Therapeutics
This trial has reported, although it was 92 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03823703 |
|---|---|
| Title | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 4, 2020 |
| Completion date | April 5, 2021 |
| Required reporting date | April 5, 2022, midnight |
| Actual reporting date | July 6, 2022 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 92 |